Duong VH - Search Results

1

Multikinase inhibitors for treating high-risk myelodysplastic syndromes: can this be brought into clinical practice?

Duong VH, Padron E, List AF, Komrokji RS. Duong VH, et al. Expert Rev Hematol. 2013 Oct;6(5):485-7. doi: 10.1586/17474086.2013.827884. Epub 2013 Oct 2. Expert Rev Hematol. 2013. PMID: 24083503 No abstract available.

2

Phase II pilot study of oral dasatinib in patients with higher-risk myelodysplastic syndrome (MDS) who failed conventional therapy.

Duong VH, Jaglal MV, Zhang L, Kale V, Lancet JE, Komrokji RS, List AF. Duong VH, et al. Leuk Res. 2013 Mar;37(3):300-4. doi: 10.1016/j.leukres.2012.11.001. Epub 2012 Dec 27. Leuk Res. 2013. PMID: 23273539 Clinical Trial.

3

Outcome of azacitidine treatment in patients with therapy-related myeloid neoplasms with assessment of prognostic risk stratification models.

Duong VH, Lancet JE, Alrawi E, Al-Ali NH, Perkins J, Field T, Epling-Burnette PK, Zhang L, List AF, Komrokji RS. Duong VH, et al. Leuk Res. 2013 May;37(5):510-5. doi: 10.1016/j.leukres.2012.12.012. Epub 2013 Jan 16. Leuk Res. 2013. PMID: 23332452 Clinical Trial.

4

Efficacy and safety of lenalidomide in patients with myelodysplastic syndrome with chromosome 5q deletion.

Duong VH, Komrokji RS, List AF. Duong VH, et al. Ther Adv Hematol. 2012 Apr;3(2):105-16. doi: 10.1177/2040620711435659. Ther Adv Hematol. 2012. PMID: 23556117 Free PMC article.

5

Poor outcome of patients with myelodysplastic syndrome after azacitidine treatment failure.

Duong VH, Lin K, Reljic T, Kumar A, Al Ali NH, Lancet JE, List AF, Komrokji RS. Duong VH, et al. Clin Lymphoma Myeloma Leuk. 2013 Dec;13(6):711-5. doi: 10.1016/j.clml.2013.07.007. Epub 2013 Sep 17. Clin Lymphoma Myeloma Leuk. 2013. PMID: 24054159

6

Cladribine, cytarabine, filgrastim, and mitoxantrone (CLAG-M) compared to standard induction in acute myeloid leukemia from myelodysplastic syndrome after azanucleoside failure.

Jaglal MV, Duong VH, Bello CM, Al Ali NH, Padron E, Fernandez HF, List AF, Lancet JE, Komrokji RS. Jaglal MV, et al. Among authors: duong vh. Leuk Res. 2014 Apr;38(4):443-6. doi: 10.1016/j.leukres.2013.12.010. Epub 2013 Dec 25. Leuk Res. 2014. PMID: 24439565

7

The role of pacritinib in the management of myelofibrosis.

Duong VH, Komrokji RS. Duong VH, et al. Expert Rev Hematol. 2014 Jun;7(3):325-32. doi: 10.1586/17474086.2014.905200. Epub 2014 Apr 21. Expert Rev Hematol. 2014. PMID: 24746271

8

Update on the pharmacotherapy for myelodysplastic syndromes.

Duong VH, Komrokji RS, List AF. Duong VH, et al. Expert Opin Pharmacother. 2014 Sep;15(13):1811-25. doi: 10.1517/14656566.2014.937705. Epub 2014 Jul 31. Expert Opin Pharmacother. 2014. PMID: 25080144 Review.

9

Lack of objective response of myelodysplastic syndromes and acute myeloid leukemia to decitabine after failure of azacitidine.

Duong VH, Bhatnagar B, Zandberg DP, Vannorsdall EJ, Tidwell ML, Chen Q, Baer MR. Duong VH, et al. Leuk Lymphoma. 2015 Jun;56(6):1718-22. doi: 10.3109/10428194.2014.966708. Epub 2014 Nov 3. Leuk Lymphoma. 2015. PMID: 25263320

10

Eltrombopag Use in Patients With Chronic Myelomonocytic Leukemia (CMML): A Cautionary Tale.

Ramadan H, Duong VH, Al Ali N, Padron E, Zhang L, Lancet JE, List AF, Komrokji RS. Ramadan H, et al. Among authors: duong vh. Clin Lymphoma Myeloma Leuk. 2016 Aug;16 Suppl:S64-6. doi: 10.1016/j.clml.2016.02.009. Clin Lymphoma Myeloma Leuk. 2016. PMID: 27521328 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

89 results

Search Page

Filters